Free Trial

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by OneDigital Investment Advisors LLC

Vertex Pharmaceuticals logo with Medical background

OneDigital Investment Advisors LLC decreased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 35.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,755 shares of the pharmaceutical company's stock after selling 945 shares during the quarter. OneDigital Investment Advisors LLC's holdings in Vertex Pharmaceuticals were worth $851,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. Aries Wealth Management purchased a new position in Vertex Pharmaceuticals in the first quarter worth $293,000. Polar Asset Management Partners Inc. purchased a new position in Vertex Pharmaceuticals in the fourth quarter worth $22,954,000. Brighton Jones LLC boosted its position in Vertex Pharmaceuticals by 45.0% during the first quarter. Brighton Jones LLC now owns 6,421 shares of the pharmaceutical company's stock valued at $3,113,000 after buying an additional 1,994 shares during the period. GAMMA Investing LLC boosted its position in Vertex Pharmaceuticals by 25.1% during the first quarter. GAMMA Investing LLC now owns 5,002 shares of the pharmaceutical company's stock valued at $2,425,000 after buying an additional 1,005 shares during the period. Finally, APG Asset Management N.V. boosted its position in Vertex Pharmaceuticals by 189.7% during the fourth quarter. APG Asset Management N.V. now owns 359,285 shares of the pharmaceutical company's stock valued at $139,724,000 after buying an additional 235,265 shares during the period. Institutional investors own 90.96% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on VRTX shares. Wolfe Research lowered shares of Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a research report on Wednesday, May 7th. Scotiabank dropped their target price on shares of Vertex Pharmaceuticals from $450.00 to $442.00 and set a "sector perform" rating for the company in a report on Tuesday, May 6th. Leerink Partners reiterated a "market perform" rating and set a $503.00 target price (down from $550.00) on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Erste Group Bank lowered shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, May 23rd. Finally, Leerink Partnrs lowered shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 6th. Fourteen investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $511.62.

Get Our Latest Report on Vertex Pharmaceuticals

Vertex Pharmaceuticals Stock Down 2.2%

VRTX stock traded down $10.68 on Friday, hitting $468.85. 892,738 shares of the company's stock were exchanged, compared to its average volume of 1,424,305. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The firm has a 50 day moving average price of $447.71 and a two-hundred day moving average price of $460.40. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.65. The stock has a market cap of $120.40 billion, a P/E ratio of -119.60 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The business's revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.76 EPS. As a group, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Read More

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?

Before you consider Vertex Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.

While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines